Patents Assigned to Biokier, Inc.
-
Publication number: 20240165060Abstract: The present invention relates to a method and composition of treating a lipid related disease such as diabetes, obesity, hypercholesterolemia, and the like by delivery of butyrate directly to the colon by bypassing the upper digestive tract in combination with a second composition that lowers cholesterol, LDL cholesterol and non-LDL cholesterol.Type: ApplicationFiled: February 2, 2024Publication date: May 23, 2024Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20230190686Abstract: A method of treating a lipid related disease by oral delivery of butyric acid to the colon for release from about 5 and about 20 hours.Type: ApplicationFiled: December 17, 2021Publication date: June 22, 2023Applicant: BIOKIER, INC.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20230149300Abstract: A method of treating diabetes Type 2, prediabetes, and diseases caused thereby, by delivery of butyric acid, to the colon by bypassing the upper digestive tract wherein release is from 0 to about 5 hours.Type: ApplicationFiled: December 21, 2021Publication date: May 18, 2023Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20230133176Abstract: The present invention relates to a method of treating diabetes Type II by oral delivery of butyric acid, and a DPP-IV inhibitor such as vildagliptin only to the ileum bypassing the stomach, duodenum and jejunum.Type: ApplicationFiled: November 4, 2021Publication date: May 4, 2023Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20220387305Abstract: A method of treating diabetes Type 2 by delivery of butyric acid, bile acid, long-chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract, with the composition combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.Type: ApplicationFiled: August 18, 2022Publication date: December 8, 2022Applicant: Biokier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20220071895Abstract: A method of treating diabetes Type 2, prediabetes, and diseases caused thereby, by delivery of butyric acid, to the colon by bypassing the upper digestive tract wherein release is from 0 to about 5 hours.Type: ApplicationFiled: November 16, 2021Publication date: March 10, 2022Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20220054406Abstract: The present invention relates to a method of treating diabetes Type II by oral delivery of butyric acid, and a DPP-IV inhibitor such as vildagliptin only to the ileum bypassing the stomach, duodenum and jejunum.Type: ApplicationFiled: November 4, 2021Publication date: February 24, 2022Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20210267919Abstract: The present invention relates to coated butyrate and butyrate plus DPP-IV inhibitor tablets. It has been discovered that an inner butyrate core, a first layer neutral polymer which can dissolve in the colon, followed by an outer coating of a composition, which dissolves only in the colon, prevents the interaction of butyrate with these compositions.Type: ApplicationFiled: February 28, 2020Publication date: September 2, 2021Applicant: BioKier, Inc.Inventors: Jerzy Ryszard Szewczyk, Nicolas D. Kirkland, Troy A. Bartron, JR., Abdul Waseh Basit
-
Publication number: 20190262262Abstract: The present invention relates to a method of treating diabetes Type II by delivery of butyric acid, bile acid, long-chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.Type: ApplicationFiled: May 7, 2019Publication date: August 29, 2019Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Patent number: 9314444Abstract: The present invention relates to a method of treating NASH or NAFLD by delivery of an effective amount of a composition comprising L-glutamine or butyric acid formulated for release in the colon by bypassing the upper digestive tract and stomach.Type: GrantFiled: February 10, 2015Date of Patent: April 19, 2016Assignee: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Patent number: 9301938Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.Type: GrantFiled: September 22, 2010Date of Patent: April 5, 2016Assignee: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20150224081Abstract: The present invention relates to a method of treating diabetes Type II by delivery of butyric acid, bile acid, long-chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.Type: ApplicationFiled: April 24, 2015Publication date: August 13, 2015Applicant: BIOKIER, INC.Inventor: Jerzy Ryszard Szewczyk
-
Patent number: 9006288Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.Type: GrantFiled: September 6, 2013Date of Patent: April 14, 2015Assignee: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20150073057Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of metformin to the colon by bypassing the upper digestive tract.Type: ApplicationFiled: September 6, 2013Publication date: March 12, 2015Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20140011876Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.Type: ApplicationFiled: September 6, 2013Publication date: January 9, 2014Applicant: BioKier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Patent number: 8470885Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract.Type: GrantFiled: January 11, 2010Date of Patent: June 25, 2013Assignee: Biokier, Inc.Inventor: Jerzy Ryszard Szewczyk
-
Publication number: 20130102581Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract.Type: ApplicationFiled: October 8, 2012Publication date: April 25, 2013Applicant: BioKier, Inc.Inventor: BioKier, Inc.
-
Publication number: 20120183617Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.Type: ApplicationFiled: September 22, 2010Publication date: July 19, 2012Applicant: Biokier, Inc.Inventor: Jerzy Ryszard Szewczyk